ACH vs card for research peptides

Query focus: ACH vs card research peptides

Switching from cards to ACH (or crypto) changes the payment rail. It does not erase product legality questions, platform policy, or high-risk classification. Residual compliance and underwriting risk remain with the business model.

RetryHub helps with merchant-account placement and underwriting prep; PayFresco is a separate payments + CRM / orchestration product.

What changes — and what does not

May change: network monitoring programs, chargeback mechanics, settlement timing, bank partner appetite for ACH vs card.
Does not change: whether the catalog is lawful for how you market and ship it; whether RUO language matches intended use; whether compounding or prescription models need separate pharmacy frameworks.

RUO ≠ FDA clearance

Research-use-only labeling is not the same as FDA clearance or approval for human use. FDA warning letters commonly analyze intended use (marketing, claims, and how a product is positioned) over disclaimer text alone. Operators should read current FDA warning letters on fda.gov for intended-use findings rather than relying on second-hand quotes. This page does not invent letter text.

Keep RUO ecommerce separate from compounding paths

RUO ecommerce, 503A/503B compounding, and GLP-1 shortage compounding are separate models. Do not blend them when comparing ACH vs card. Each has different licensing, marketing, and underwriting expectations.

Practical underwriting framing

If you process cards, ACH, or both, document product claims, policies, fulfillment, and prior processor outcomes honestly. ACH or crypto alone is not a remediation plan for a declined or restricted card account. RetryHub industry context: peptides and research chemicals.

Apply: retryhub.com/apply